Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adeno-associated virus expression systems for gene transfer

J E Rabinowitz1, J Samulski

  • 1Human Gene Therapy Center, University of North Carolina at Chapel Hill 27599-7352, USA. jerabin@med.unc.edu

Current Opinion in Biotechnology
|November 20, 1998
PubMed
Summary

Adeno-associated virus vectors offer long-term gene expression without toxicity or immune response. Improved production methods enhance their in vivo use, paving the way for human clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endostatin therapy reveals a U-shaped curve for antitumor activity.

Cancer gene therapy·2006
Same author

Vector biophysics: crystal-clear view.

Gene therapy·2002
Same author

Building a better vector: the manipulation of AAV virions.

Virology·2000
Same author

Insertional mutagenesis of AAV2 capsid and the production of recombinant virus.

Virology·1999
Same author

Gene therapy in the United States: a five-year status report.

Human gene therapy·1996
Same author

Targeted mutation of Ncam to produce a secreted molecule results in a dominant embryonic lethality.

Proceedings of the National Academy of Sciences of the United States of America·1996

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Viral Vector Technology

Background:

  • Adeno-associated virus (AAV) vectors are promising for gene therapy.
  • Traditional gene delivery systems often elicit immune responses or toxicity.
  • Long-term gene expression is crucial for effective therapeutic outcomes.

Purpose of the Study:

  • To highlight the advantages of AAV vectors over other gene delivery systems.
  • To discuss recent advancements in AAV vector production.
  • To underscore the potential of AAV vectors for clinical applications.

Main Methods:

  • Review of existing literature on AAV vector technology.
  • Analysis of new production methods for AAV vectors.
  • Evaluation of AAV vector performance in preclinical studies.

Related Experiment Videos

Main Results:

  • AAV vectors demonstrate sustained gene expression.
  • AAV vectors exhibit minimal immunogenicity and toxicity.
  • Novel production techniques have significantly improved vector yield and purity.

Conclusions:

  • AAV vectors represent a safe and effective gene delivery platform.
  • Enhanced production methods facilitate robust in vivo gene therapy.
  • Further preclinical studies will support the translation of AAV vectors into human clinical trials.